组织生物标志物特征在透明细胞肾细胞癌中的预后价值
本研究纳入367例非转移性透明细胞肾细胞癌患者,分为训练集与验证集,对24种生物标志物进行免疫染色,经LASSO Cox回归筛选出5种标志物构建复发风险分类器。中位随访63.5个月,低、中、高风险组5年无复发生发生存率分别为93.8%、87.7%和70%(P < 0.001);高风险评分患者在多因素分析中无复发生存更差(HR 3.66,95%CI 1.58-8.49,P = 0.003)。该五标志物分类器提高了临床模型的一致性指数。
要点
- LASSO Cox回归从24种标志物中选出N-cadherin、E-cadherin、Ki67、cyclin D1和p-4EBP1共5种构建复发风险分类器。
- 按风险评分三分位分为低、中、高风险组,5年无复发生存率分别为93.8%、87.7%和70%(P < 0.001)。
- 高风险评分患者无复发生存更差(HR 3.66,95%CI 1.58-8.49,P = 0.003),分类器提高训练集与验证集临床模型的一致性指数。
核心结论
- 开发出基于5种标志物的预后工具,可有效对透明细胞肾细胞癌患者术后疾病复发风险进行分类;若经前瞻性验证,该工具可为患者提供个体化风险评估。
研究设计与样本
- 纳入367例非转移性透明细胞肾细胞癌患者,队列分为训练集与验证集。
- 使用组织微阵列对24种代表透明细胞肾细胞癌关键通路的生物标志物进行免疫染色。
- 采用LASSO Cox回归筛选标志物并构建疾病复发风险分类器。
主要发现
- 中位(四分位距)随访63.5(24.0-85.3)个月。
- LASSO Cox回归从24种标志物中选出5种用于风险分类器:N-cadherin、E-cadherin、Ki67、cyclin D1和磷酸化真核起始因子4E结合蛋白-1(p-4EBP1)。
- 按风险评分三分位将患者分为低、中、高风险复发;5年无复发生存率低风险组为93.8%、中风险组为87.7%、高风险组为70%(P < 0.001)。
- 调整年龄、性别、种族和Mayo Clinic分期、大小、分级和坏死(SSIGN)评分后,多因素分析显示高标志物评分患者无复发生存更差(整体队列中高风险评分 vs 低风险评分:HR 3.66,95%CI 1.58-8.49,P = 0.003)。
- 五标志物分类器在训练集和验证集中均提高了临床模型的一致性指数。
临床怎么用
- 原文未据此给出推荐;作者指出该五标志物预后工具若经前瞻性验证,可为透明细胞肾细胞癌患者提供个体化复发风险评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To improve risk stratification for recurrence prognostication in patients with localised clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: In all, 367 patients with non-metastatic ccRCC were included. The cohort was divided into a training and validation set. Using tissue microarrays, immunostaining was performed for 24 biomarkers representative of key pathways in ccRCC. Using Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression, we identified several markers that were used to construct a risk classifier for risk of disease recurrence. RESULTS: The median (interquartile range) follow-up was 63.5 (24.0-85.3) months. Five out of 24 markers were selected by LASSO Cox regression for the risk classifier: N-cadherin, E-cadherin, Ki67, cyclin D1 and phosphorylated eukaryotic initiation factor 4E binding protein-1 (p-4EBP1). Patients were classified as either low, intermediate or high risk of disease recurrence by tertiles of risk score. The 5-year recurrence-free survival (RFS) was 93.8%, 87.7% and 70% for patients with low-, intermediate- and high-risk scores, respectively (P < 0.001). Patients with a high marker score had worse RFS on multivariate analysis adjusted for age, gender, race and the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) score (hazard ratio 3.66, 95% confidence interval 1.58-8.49, P = 0.003 for high vs low marker score in the overall cohort). The five-marker classifier increased the concordance index of the clinical model in both the training and validation sets. CONCLUSION: We developed a five-marker-based prognostic tool that can effectively classify patients with ccRCC according to risk of disease recurrence after surgery. This tool, if prospectively validated, could provide individualised risk estimation for patients with ccRCC.
引用
- Haddad AQ, Luo JH, Krabbe LM, et al. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma. BJU Int. 2017. PMID: 28075543. doi:10.1111/bju.13776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。